It’s something I’ll probably spend time looking into after the FDA gives us approval for Revascor … the market as it is will be more than enough to keep MSB busy for many years scaling up… any long COVID impacts will just mean the total addressable market gets even larger.
but I think simple things like diet and lifestyle are things that will always be a leading factor in heart failure, so until that changes dramatically then the TAM will keep growing
Ann: Mesoblast Update on Chronic Low Back Pain Program, page-327
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.21 |
Change
0.040(3.42%) |
Mkt cap ! $1.381B | |||
| Open | High | Low | Value | Volume |
| $1.17 | $1.22 | $1.17 | $5.683M | 4.776M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | $1.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.21 | 19746 | 3 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |